The criteria used to assess whether a problem is of public health importance (and therefore
should be a priority for health services) include the prevalence of the problem, the severity of …

Objective: Patients with major depressive disorder (MDD) experience sleep disturbances
that may be worsened by some antidepressant drugs early in treatment. The aim of this …

Sleep disturbances are often associated with depression and mood disorders, and certain
manipulations of the sleep–wake cycle are effective as therapeutic interventions in the …

This open study evaluates the effect of agomelatine, a melatonergic receptor agonist and 5-
HT2C antagonist antidepressant, on sleep architecture in patients suffering from major …

The efficacy of agomelatine in severe depression has been examined in three positive
placebo-controlled studies and in a pooled analysis of the data from the three studies in …

All known antidepressants enhance monoamine neurotransmission, and most do so by
blocking one or more of the reuptake transporters for serotonin, norepinephrine and/or …

Agomelatine is a novel agent that is under late-stage development as a potential
antidepressant. Compared with available antidepressant agents, the drug may have a …

Depressive disorders are of the highest socioeconomic and health-economic importance, as
they are the psychiatric disorders that most frequently cause psychosocial disability. Despite …

This article reviews the novel atypical antidepressant drug agomelatine (Valdoxan), which is
currently being actively investigated in the United States for the treatment of depression but …

Full remission of symptoms is the goal for the acute treatment of depression, because
incomplete remission is associated with poor outcomes including higher risk of relapse and …